- Home
- RNG vs TNGX Comparison
RNG vs TNGX Comparison
Compare RNG & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNG | TNGX |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 4.1B |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RNG | TNGX |
|---|---|---|
| Price | $79.35 | $23.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 13 |
| Target Price | ★ $57.64 | $44.88 |
| AVG Volume (30 Days) | 1.4M | ★ 3.6M |
| Earning Date | 10-22-2026 | 11-03-2026 |
| Dividend Yield | ★ 0.66% | N/A |
| EPS Growth | ★ 176.19 | 26.89 |
| EPS | ★ 0.80 | N/A |
| Revenue | ★ $2,515,142,000.00 | $62,384,000.00 |
| Revenue This Year | $5.02 | N/A |
| Revenue Next Year | $4.53 | N/A |
| P/E Ratio | $94.47 | ★ N/A |
| Revenue Growth | 4.78 | ★ 48.29 |
| 52 Week Low | $24.14 | $6.69 |
| 52 Week High | $81.90 | $34.39 |
Technical Indicators
Market Signals| Indicator | RNG | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 54.12 | 48.18 |
| Support Level | $72.29 | $19.99 |
| Resistance Level | $77.95 | $25.42 |
| Average True Range (ATR) | 3.33 | 1.40 |
| MACD | -0.54 | -0.03 |
| Stochastic Oscillator | 48.18 | 45.84 |
Price Performance
Historical ComparisonAbout RNG RingCentral Inc.
RingCentral is a unified communications as a service, or UCaaS, provider. Its software helps users communicate and collaborate via voice, video, and messaging across all device types and all from one platform. RingCentral helps customers modernize and move from legacy on-premises systems to modern, cloud-based systems. Beyond its core RingCentral MVP solution, RingCentral also offers a cloud-based contact center solution, a stand-alone video meetings solution, and webinars.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.